despit
effort
improv
hygien
infecti
diarrhea
respons
earli
childhood
recent
multicent
studi
life
threaten
diarrhea
conduct
indian
subcontin
subsaharan
africa
found
littlestudi
apicomplexan
parasit
cryptosporidium
predominantli
either
cryptosporidium
parvum
cryptosporidium
homini
amongst
two
three
import
caus
childhood
cryptosporidiosi
also
strongli
associ
child
malnutrit
development
cryptosporidium
parasit
previous
best
known
frequent
caus
chronic
diarrhea
immunocompromis
peopl
aid
follow
organ
transplant
unit
state
account
waterborn
diarrheal
diseas
pathogen
cryptosporidiosi
also
larg
econom
concern
beef
milk
produc
infect
cattl
may
contribut
contamin
water
suppli
human
nationwid
survey
farm
unit
state
c
parvum
present
dairi
farm
calv
age
week
despit
public
health
econom
impact
cryptosporidium
prevent
vaccin
treatment
option
human
cattl
limit
approv
treatment
nitazoxanid
reduc
durat
diarrhea
immunocompet
adult
moder
effect
children
equival
placebo
immunocompromis
activ
dairi
calv
controversi
best
new
anticryptosporidium
drug
urgent
need
sever
promis
drug
lead
report
benzoxaborol
easili
synthes
boronheterocycl
compound
garner
interest
pharmaceut
industri
last
typic
engag
protein
interact
electrophil
boron
atom
nucleophil
partner
residu
eg
serin
threonin
tyrosin
metal
cation
eg
present
activ
site
enzym
act
phosphat
mimet
potent
benzoxaborol
inhibitor
pathogen
identifi
work
inhibit
variou
essenti
microbi
tavaborol
leucyltrna
synthetas
inhibitor
approv
treatment
onychomycosi
crisaborol
target
human
phosphodiesteras
recent
approv
treatment
atop
plasmodium
parasit
caus
malaria
member
phylum
apicomplexa
therefor
genet
relat
cryptosporidium
parasit
given
recent
identif
benzoxaborol
potent
antimalari
screen
librari
benzoxaborol
compound
anticryptosporidi
activ
report
identif
novel
drug
candid
treatment
cryptosporidiosi
potent
inhibit
multipl
c
parvum
isol
c
homini
isol
vitro
appear
parasiticid
outstand
activ
rodent
model
acut
establish
infect
efficaci
c
parvum
dairi
calf
clinic
model
initi
pharmacokinet
pk
stabil
safeti
profil
highli
favor
indic
potenti
new
drug
treat
cryptosporidiosi
target
popul
meet
need
new
anticryptosporidi
drug
candid
adopt
drug
reposit
strategi
capit
exist
benzoxaborol
scaffold
knowledg
advanc
program
within
anacor
neglect
tropic
diseas
portfolio
includ
antikinetoplastid
program
drug
neglect
diseas
initi
dndi
global
allianc
veterinari
medicin
galvm
antimalari
program
medicin
malaria
ventur
mmv
intern
antibacteri
leucyltrna
synthetas
leur
inhibitor
program
librari
compound
includ
analog
similar
four
chemic
scaffold
antiprotozo
activ
screen
duplic
inhibit
c
parvum
growth
within
mdck
cell
use
high
content
microscopi
adapt
previous
describ
screen
assay
fig
screen
yield
hit
inhibit
concentr
confirmatori
doserespons
assay
conduct
triplic
compound
avail
followup
addit
compound
test
complet
structur
activ
relationship
sar
analys
scaffold
priorit
done
conduct
preliminari
mous
efficaci
studi
one
compound
repres
chemic
scaffold
select
base
avail
chemic
stock
exist
potenc
mous
pk
data
potenti
leverag
program
within
anacor
neglect
tropic
diseas
portfolio
select
develop
base
consider
remain
scaffold
retain
altern
worthi
revisit
necessari
fig
benzoxaborol
repres
class
compound
activ
trypanosoma
brucei
caus
human
african
trypanosomiasi
hat
class
compound
current
human
exhibit
favor
pk
properti
anim
human
eg
prolong
exposur
halflif
potenti
provid
singledos
cure
relat
benzoxaborol
class
also
shown
good
vitro
activ
human
african
trypanosomiasi
hat
due
br
brucei
br
gambiens
br
rhodesiens
african
anim
trypanosomiasi
aat
due
congolens
member
class
also
shown
favor
safeti
profil
enhanc
statu
reposit
strategi
program
structur
puriti
determin
nmr
nmr
high
resolut
mass
spectral
analysi
hrm
high
perform
liquid
chromatographi
hplc
supplementari
fig
vitro
inhibit
bunch
grass
farm
bgf
c
parvum
iowa
isol
h
exposur
cell
confirm
repeatedli
measur
rang
compar
activ
observ
inhibit
field
c
parvum
isol
c
parvum
iowa
isol
sourc
univers
arizona
sterl
laboratori
isol
propag
independ
bgf
isol
year
also
inhibit
c
homini
isol
higher
fig
cytotox
assess
three
cell
line
observ
concentr
ie
highest
concentr
test
supplementari
tabl
yield
select
index
inhibit
cryptosporidium
greater
case
anticryptosporidi
activ
examin
use
panel
vitro
assay
determin
mode
activ
assay
c
parvum
invas
host
cell
supplementari
fig
predominantli
affect
intracellular
cryptosporidium
develop
sinc
arrest
new
dna
synthesi
reflect
inhibit
incorpor
thymidin
analog
edu
newli
synthes
dna
fig
rel
effect
differ
life
cycl
stage
assess
compar
potenc
asexu
replic
potenc
reduc
percent
parasit
express
meiotic
recombin
protein
biomark
cryptosporidium
sexual
unlik
compound
eg
piperazinebas
lead
equal
potenc
asexu
sexual
stage
inhibit
asexu
parasit
growth
four
time
potent
asexualstag
sexualstag
differenti
fig
felt
consist
effect
intracellular
replic
treatment
cryptosporidiosi
immunocompromis
individu
malnourish
children
aid
patient
transplant
patient
might
expect
requir
parasiticid
compound
consist
hypothesi
c
parvum
timekil
curv
assay
show
approv
drug
nitazoxanid
effect
immunocompet
adult
equival
placebo
aid
patient
like
parasitistat
slow
act
fig
timekil
curv
data
referenc
vehicl
control
time
point
order
isol
effect
compound
spontan
declin
c
parvum
number
occur
h
vitro
cultur
demonstr
absenc
nitazoxanidedepend
parasit
elimin
fig
hand
appear
act
rapidli
drove
progress
elimin
c
parvum
vitro
absenc
immun
pressur
fig
vitro
parasit
elimin
presenc
exponenti
halflif
h
h
requir
parasit
reduct
maximum
rate
parasit
elimin
achiev
anticip
progress
mous
calf
model
cryptosporidiosi
evalu
pharmacokinet
properti
speci
administ
intraven
mice
dose
mg
per
kg
solut
polyethylen
glycolpropylen
glycolwat
vehicl
exhibit
high
cmax
per
ml
low
clearanc
cl
high
exposur
long
halflif
h
administ
oral
mice
dose
mg
per
kg
suspens
aqueou
vehicl
show
high
cmax
per
ml
exposur
long
halflif
h
modest
bioavail
f
supplementari
tabl
supplementari
fig
dose
oral
calv
dose
mg
per
kg
aqueou
vehicl
exhibit
high
cmax
per
ml
high
exposur
halflif
five
time
greater
seen
mice
h
supplementari
fig
mous
calf
pk
studi
also
quantifi
fece
expect
least
antiparasit
activ
could
relat
direct
exposur
parasit
drug
matrix
mous
studi
concentr
fece
gener
increas
h
period
follow
oral
dose
highli
variabl
supplementari
fig
calv
dose
oral
consider
lower
variabl
observ
anim
concentr
remain
high
entir
h
observ
period
supplementari
fig
efficaci
first
test
vivo
use
nod
scid
nod
scid
gamma
nsg
mous
model
model
establish
c
parvum
treatment
begun
day
infect
mice
oral
gavag
c
parvum
bunch
grass
farm
iowa
isol
posit
control
compound
paromomycin
reduc
fecal
parasit
shed
day
treatment
hand
day
treatment
reduc
parasit
shed
dose
mg
per
kg
dose
mg
per
kg
administ
daili
oral
gavag
fig
nsg
mice
treat
gain
weight
normal
advers
effect
observ
interferon
gamma
knockout
ko
mous
anoth
wide
use
cryptosporidium
anim
unlik
lethal
infect
report
investig
c
parvum
infect
ko
mice
produc
selfresolv
acut
infect
hand
variou
dose
test
use
model
c
parvum
univers
arizona
iowa
isol
clofazimin
parasitistat
lack
efficaci
cryptosporidium
nsg
use
posit
demonstr
dosedepend
efficaci
includ
efficaci
dose
mg
per
kg
daili
maxim
efficaci
similar
seen
clofazimin
fig
case
nsg
mice
caus
advers
effect
ko
mice
mice
infect
c
parvum
develop
diarrhea
neonat
dairi
calv
infect
c
parvum
develop
selflimit
ill
much
like
seen
infant
character
sever
wateri
diarrhea
dehydr
fecal
oocyst
therefor
use
neonat
calf
model
test
effect
treatment
diarrhea
dehydr
addit
effect
parasit
shed
initi
small
efficaci
studi
conduct
effect
infect
pk
also
assess
data
use
guid
design
addit
dose
regimen
fig
onedayold
twodayold
bull
calv
infect
oral
administr
c
parvum
bunch
grass
farm
iowa
isol
oocyst
fecal
parasit
shed
measur
daili
use
qpcr
anim
assess
clinic
least
twice
daili
diarrhea
hydrat
statu
appetit
overal
health
statu
clinic
observ
quantifi
use
previous
describ
scale
rang
normal
sever
abnorm
fecal
consist
overal
health
statu
hydrat
statu
appetit
see
supplementari
tabl
final
area
time
cours
curv
auc
calcul
provid
overal
measur
impact
paramet
facilit
statist
comparison
calv
toler
well
base
least
twice
daili
assess
alert
interact
caregiv
appetit
see
supplementari
tabl
clinic
score
rubric
effect
oral
mg
per
kg
twice
daili
mg
per
kg
daili
vehicl
alon
first
compar
begun
day
infect
continu
day
plasma
fecal
exposur
infect
inlin
predict
base
result
uninfect
calv
although
fecal
level
vari
wide
first
day
dose
supplementari
fig
twice
daili
mg
per
kg
curtail
parasit
shed
complet
elimin
diarrhea
fig
e
daili
mg
per
kg
also
reduc
peak
parasit
shed
diarrhea
howev
despit
equal
better
mean
plasma
exposur
anim
treat
daili
mg
per
kg
vs
twice
daili
mg
per
kg
fecal
parasit
shed
resum
persist
daili
treat
anim
fig
base
data
unlik
plasma
exposur
alon
drive
efficaci
suggest
gastrointestin
exposur
import
major
question
address
second
calf
studi
includ
whether
dose
durat
could
shorten
whether
fulli
sick
anim
would
respond
treatment
question
address
respect
test
regimen
mg
per
kg
three
time
daili
test
efficaci
mg
per
kg
twice
daili
day
treatment
delay
peak
diarrhea
even
administ
begin
peak
symptom
day
infect
twice
daili
mg
per
kg
cure
diarrhea
day
faster
control
parasit
shed
abolish
day
fig
total
parasit
shed
reduc
greater
log
fig
treatment
mg
per
kg
three
time
per
day
day
elimin
diarrhea
reduc
rate
parasit
shed
log
treatment
howev
parasitolog
relaps
follow
fig
suggest
day
day
treatment
requir
final
sever
treatment
regimen
significantli
reduc
overal
sever
dehydr
fig
surpris
result
given
anim
receiv
aggress
treatment
minim
dehydr
possess
favor
stabil
pk
eg
mous
h
safeti
characterist
supplementari
tabl
supplementari
tabl
neg
ame
test
mutagen
potenti
neg
vitro
micronucleu
genotox
assay
signific
find
ricerca
bioscienc
lead
profil
advers
reaction
enzym
offtargetpanel
total
assay
neg
inhibit
herg
k
ion
channel
associ
cardiac
tachyarrhythmia
administr
daili
oral
gavag
male
rat
mg
per
kg
per
day
seven
day
well
toler
clinic
sign
eg
chang
activ
groom
see
method
weight
loss
chang
food
consumpt
patholog
observ
slight
chang
red
blood
cell
paramet
serum
alkalin
phosphatas
serum
triglycerid
occur
consid
clinic
signific
compound
accumul
observ
toxicokinet
analysi
done
parallel
supplementari
tabl
base
data
observ
advers
effect
level
noael
conclud
greater
mg
per
kg
per
day
rat
addit
toxicolog
studi
includ
higher
dose
need
ascertain
complet
preclin
pictur
studi
collect
identifi
promis
candid
new
cryptosporidiosi
treatment
activ
vitro
c
homini
c
parvum
unlik
compound
nitazoxanid
lack
efficaci
sever
immunocompromis
mice
peopl
rapidli
elimin
c
parvum
vitro
efficaci
immunocompromis
mice
thu
may
use
treatment
patient
popul
affect
cryptosporidiosi
includ
aid
patient
transplant
recipi
malnourish
children
addit
efficaci
mous
model
acut
establish
infect
reduc
c
parvum
fecal
shed
diarrhea
dehydr
neonat
calf
model
diseas
close
mimic
seen
infant
also
meet
mani
stabil
safeti
requir
novel
although
addit
toxicolog
pk
studi
need
note
less
potent
vitro
c
homini
isol
highlight
need
test
vivo
efficaci
c
homini
anticryptosporidi
mechan
action
remain
experiment
determin
edu
incorpor
assay
fig
result
demonstr
arrest
intracellular
cryptosporidium
develop
prior
dna
synthesi
impli
compound
directli
affect
dna
synthesi
mani
compound
directli
target
dna
synthesi
eg
sever
trnasynthetas
inhibitor
presum
inhibit
protein
synthesi
look
similar
recent
studi
demonstr
trypanicid
activ
result
inhibit
trypanosom
mrna
furthermor
relat
hat
aat
lead
compound
also
like
target
cleavag
polyadenyl
specif
factor
endonucleas
function
mrna
known
oxaborol
inhibit
plasmodium
cryptosporidium
greater
ident
p
falciparum
amino
acid
level
therefor
seem
possibl
inhibit
cryptosporidium
well
given
modest
efficaci
nitazoxanid
improv
drug
treat
cryptosporidiosi
vulner
popul
ie
malnourish
children
immunocompromis
peopl
eagerli
await
multipl
lead
compound
seri
affect
varieti
target
may
need
given
high
attrit
rate
typic
drug
develop
may
also
help
address
inevit
issu
drug
resist
either
simpli
provid
altern
drug
facilit
develop
drug
combin
reduc
likelihood
resist
evolv
toward
goal
phenotyp
screen
assay
develop
grow
number
lead
compound
phosphatidylinositol
kinas
inhibitor
repurpos
malaria
drug
develop
effort
current
advanc
compound
cryptosporidium
reduc
fecal
c
parvum
shed
rate
nearli
five
log
first
three
day
treatment
neonat
calf
model
believ
rapid
effect
yet
report
furthermor
treatment
reduc
total
burden
fecal
c
parvum
shed
ie
auc
base
efficaci
stabil
preliminari
vitro
rat
safeti
characterist
amongst
advanc
compound
current
pipelin
pois
preclin
toxicolog
studi
hope
advanc
human
clinic
trial
note
follow
primer
use
quantit
pcr
amplif
c
parvum
rrna
forwardtagagattggaggttgttcct
chemic
ident
establish
nmr
nmr
highresolut
mass
spectral
hrm
analysi
compound
puriti
assess
high
perform
liquid
chromatographi
hplc
instrument
column
venusil
mp
mm
highcont
microscopi
assay
use
measur
activ
compound
c
screen
perform
univers
california
san
francisco
use
madindarbi
canin
kidney
mdck
type
atcc
cell
grown
confluenc
clearbottom
plate
per
well
dulbecco
minimum
essenti
medium
dmem
life
technolog
heat
inactiv
fetal
bovin
serum
fb
concentr
fb
reduc
prior
addit
parasit
c
parvum
iowa
isol
oocyst
use
screen
purchas
sterl
laboratori
univers
arizona
store
use
oocyst
induc
excyst
treatment
min
mm
hcl
min
mm
sodium
taurochol
wash
medium
fb
ad
cell
monolay
presenc
compound
number
oocyst
ad
well
depend
viabil
parasit
stock
vari
experi
compound
screen
concentr
incub
h
cell
fix
least
h
ad
equal
volum
formaldehyd
pb
fixat
cell
block
titron
bovin
serum
albumin
bsa
salin
also
use
subsequ
step
cell
incub
per
ml
biotinyl
vicia
villosa
lectin
vvl
vector
laboratori
catalog
h
room
temperatur
wash
three
time
stain
dark
h
room
temperatur
per
ml
jackson
immunoresearch
catalog
contain
nm
dapi
incub
plate
wash
three
time
per
well
block
buffer
ad
plate
store
dark
process
imag
acquir
use
ge
incel
autom
microscop
ge
incel
develop
version
imag
analysi
softwar
use
quantifi
parasit
host
cell
confirm
dose
respons
curv
perform
triplic
halflog
serial
dilut
start
followup
assay
perform
univers
vermont
uvm
calibr
scripp
research
infect
colon
adenocarcinoma
cell
line
atcc
stain
vicia
villosa
lectin
fb
concentr
parasit
use
assay
indic
parasit
isol
sourc
includ
c
parvum
iowa
isol
oocyst
purchas
bunch
grass
farm
deari
id
c
parvum
iowa
isol
oocyst
purchas
sterl
laboratori
univers
arizona
tucson
az
wild
type
c
parvum
oocyst
provid
dr
jenni
zambriski
virginia
tech
blacksburg
va
c
homini
isol
purchas
dr
saul
tzipori
tuft
univers
cum
school
veterinari
medicin
north
grafton
invas
assay
dna
replic
assay
asexu
sexual
stage
convers
timekil
curv
assay
perform
use
fluoresc
microscopi
enumer
parasit
host
cell
nuclei
stain
protocol
individu
describ
assay
unless
note
otherwis
detail
imag
acquisit
follow
invert
nikon
eclips
microscop
autom
stage
perfect
focu
use
nisel
advanc
research
softwar
nikon
usa
version
imag
well
microscop
program
focu
center
well
take
composit
imag
per
well
use
na
object
imag
export
tiff
file
parasit
host
nuclei
count
use
custom
macro
imagej
nation
institut
health
version
data
analyz
use
microsoft
excel
graphpad
prism
version
host
cell
invas
assay
allow
c
parvum
invad
host
cell
monolay
presenc
compound
enumer
parasit
host
cell
h
ie
complet
parasit
divis
cycl
cell
grown
rpmi
media
supplement
u
per
ml
penicillin
per
ml
streptomycin
heat
inactiv
fetal
bovin
serum
complet
media
c
parvum
iowa
isol
oocyst
bunch
grass
farm
deari
id
use
infect
cell
reach
confluenc
media
remov
replac
per
well
fresh
media
contain
twice
indic
concentr
compound
incub
h
humidifi
incub
meantim
oocyst
induc
excyst
first
treat
mm
hydrochlor
acid
dilut
distil
water
min
follow
mm
sodium
taurochol
phosphat
buffer
salin
pb
calcium
magnesium
min
treatment
oocyst
spun
g
min
supernat
remov
oocyst
dilut
complet
media
ad
cell
oocyst
per
well
final
concentr
compound
indic
concentr
oocyst
allow
excyst
sporozoit
allow
invad
presenc
indic
compound
concentr
h
cell
wash
three
time
pb
contain
mm
dgalactos
fix
formaldehyd
min
room
temperatur
follow
permeabil
triton
min
cell
wash
three
time
pb
contain
tween
block
bovin
serum
albumin
bsa
pb
overnight
invad
parasit
stain
per
ml
fluoresceinlabel
vicia
villosa
lectin
vector
laboratori
catalog
h
follow
nuclei
stain
mm
hoechst
anaspec
catalog
min
wash
five
time
pb
contain
tween
neg
control
treat
except
one
follow
addit
prestep
heat
kill
oocyst
first
heat
kill
min
induc
excyst
fix
host
cell
cell
seed
well
plate
confluenc
fix
formaldehyd
min
room
temperatur
follow
wash
warm
complet
media
experi
measur
dna
replic
use
surrog
marker
cryptosporidium
develop
within
glass
bottom
plate
coat
per
ml
fibronectin
bd
pharmingen
catalog
accord
manufactur
protocol
cell
grown
confluenc
well
mode
action
timekil
curv
assay
perform
fb
c
parvum
iowa
isol
oocyst
bunch
grass
farm
deari
id
trigger
excyst
ad
densiti
per
well
delay
ad
follow
incub
h
addit
mm
edu
incub
edu
hour
cell
wash
fix
formaldehyd
salin
cell
permeabil
stain
incorpor
edu
use
clickit
assay
kit
thermo
fisher
scientif
catalog
imag
acquir
focus
parasit
focal
plane
top
host
cell
monolay
use
object
na
edu
lectin
number
quantifi
use
imagej
softwar
effect
asexu
vs
sexual
stage
cryptosporidium
assess
compar
potenc
reduc
percent
host
cell
infect
first
h
develop
within
cell
reflect
asexu
parasit
develop
effect
express
meiotic
recombin
protein
previous
identifi
sexual
stagespecif
ad
h
cultur
approxim
time
sexual
differenti
effect
appear
posit
parasit
measur
use
highcont
microscopi
stain
fitcconjug
vicia
villosa
lectin
dapi
antic
parvum
mous
monoclon
antibodi
clone
kappa
use
undilut
cultur
supernat
secondari
alexa
fluor
goat
antimous
igg
antibodi
invitrogen
catalog
dilut
per
ml
amphotericin
b
sigma
catalog
ad
cultur
media
per
ml
dose
respons
assay
timekil
curv
assay
use
assess
parasiticid
parasitistat
c
c
parvum
iowa
isol
oocyst
bunch
grass
farm
deari
id
treat
induc
excyst
ad
confluent
cell
plate
ad
multipl
h
infect
monolay
wash
fix
stain
vicia
villosa
lectin
dapi
indic
time
point
imag
c
parvum
growth
assay
separ
plate
use
time
point
parasit
number
normal
host
cell
nucleu
number
express
percentag
host
cell
infect
druginduc
parasit
decay
isol
reduct
parasit
time
occur
spontan
cultur
system
express
number
parasit
percentag
number
parasit
present
time
point
control
dmsotreat
condit
singledos
oral
intraven
murin
pk
studi
perform
wuxi
biolog
wuxi
china
femal
mice
complianc
anim
care
guidelin
formul
mg
per
ml
glycol
pg
water
iv
administr
mg
per
ml
carboxymethylcellulos
water
tween
oral
administr
singledos
oral
calf
pk
studi
perform
univers
vermont
complianc
anim
care
guidelin
approv
univers
vermont
institut
anim
care
use
committe
holstein
bull
calv
acquir
within
h
birth
grouphous
formul
suspens
mg
per
ml
carboxymethylcellulos
water
tween
dilut
water
achiev
concentr
need
ml
dose
dose
squirt
calv
mouth
interrupt
bottl
feed
fecal
sampl
collect
indic
time
manual
anal
stimul
mous
calf
studi
plasma
sampl
analyz
liquid
chromatographytandem
mass
spectrometri
lcmsm
sampl
concentr
calcul
use
standard
curv
compound
ad
control
plasma
fecal
measur
extract
homogen
fece
acetonitril
fece
ad
volum
acetonitril
ml
per
g
mix
vortex
min
room
temperatur
centrifug
one
hundr
microlit
sampl
dri
nitrogen
reconstitut
acetronitrilewat
analyz
lcmsm
fecal
extract
method
valid
standard
curv
compound
ad
control
fece
mean
plasma
fece
concentr
nomin
time
use
construct
semilogarithm
plasma
concentr
versu
time
curv
supplementari
fig
noncompartment
analysi
mean
concentrationtim
profil
perform
use
phoenix
version
pharsight
corpor
mountain
view
ca
usa
concentr
limit
quantit
assign
valu
zero
gener
mean
concentr
predict
multidos
exposur
gener
nonparametr
superposit
singledos
pk
data
use
phoenix
version
supplementari
fig
nod
scid
gamma
mice
nodcgprkdcscid
nsg
use
model
chronic
cryptosporidium
nsg
mous
studi
perform
complianc
anim
care
guidelin
approv
univers
vermont
institut
anim
care
use
committe
nsg
mice
normal
flora
purchas
jackson
laboratori
bar
harbor
hous
least
week
acclimat
age
four
five
week
mice
infect
oral
gavag
c
parvum
iowa
isol
bunch
grass
farm
oocyst
day
follow
infect
mice
treat
daili
oral
gavag
paromomycin
posit
control
indic
dose
compound
dissolv
dmso
dilut
hydroxypropyl
methylcellulos
hpmc
final
concentr
dmso
final
volum
fecal
parasit
shed
measur
use
quantit
pcr
qpcr
assay
primer
name
forward
interferon
gamma
knockout
mice
use
model
acut
cryptosporidium
knockout
mous
studi
perform
complianc
anim
care
guidelin
approv
explora
biolab
san
diego
ca
institut
anim
care
use
committe
fourweekold
femal
mice
normal
flora
purchas
jackson
laboratori
acclim
day
prior
infect
oral
gavag
c
parvum
iowa
isol
oocyst
sterl
laboratori
univers
arizona
suspend
steril
distil
water
indic
time
follow
infect
mice
treat
compound
vehicl
alon
clofazimin
posit
control
daili
indic
dose
fecal
parasit
shed
measur
isol
oocyst
use
sucros
gradient
centrifug
sheather
sucros
solut
freshli
prepar
dissolv
g
sucros
ml
phenol
ml
water
two
sucros
solut
prepar
specif
graviti
sheather
tween
pb
b
specif
graviti
sheather
tween
pb
ml
microfug
tube
gradient
prepar
lay
ml
solut
care
lay
ml
solut
b
slowli
prevent
mix
two
layer
fecal
pellet
remov
storag
homogen
vortex
pipet
ml
fecal
homogen
overlaid
top
gradient
microfug
tube
oocyst
float
fece
centrifug
g
min
collect
pipet
tip
specif
graviti
interfac
solut
b
oocyst
rins
cold
pb
pellet
centrifug
g
min
resuspend
pb
isol
oocyst
stain
fluorescein
isothiocyanateconjug
mous
anticryptosporidium
antibodi
biorad
catalog
f
per
sampl
quantifi
use
guava
easycyt
flow
cytomet
cytosoft
data
acquisit
softwar
version
guava
technolog
inc
oocyst
per
millilit
sampl
normal
count
per
milligram
fece
calf
efficaci
studi
perform
previous
studi
approv
univers
vermont
institut
anim
care
use
committe
conduct
complianc
usdaaphi
blue
book
avail
wwwaphisusdagovanimalwelfar
holstein
bull
calv
acquir
birth
green
mountain
dairi
sheldon
vt
given
synthet
colostrum
g
igg
land
lake
ardent
hill
mo
bovin
coronaviru
escherichia
coli
antibodi
first
defens
bolu
immuncel
corpor
portland
within
h
birth
transport
uvm
calv
grouphous
initi
infect
h
age
interrupt
bottl
feed
oral
administr
c
parvum
iowa
isol
oocyst
bunch
grass
farm
deari
id
suspend
ml
water
move
individu
rais
pen
observ
twice
daili
feed
time
clinic
sign
quantifi
accord
previous
describ
standard
score
data
fecal
consist
dehydr
overal
health
collect
case
score
normal
sever
abnorm
score
rubric
supplementari
tabl
clinic
microbiolog
studi
adventiti
infecti
agent
includ
salmonella
cultur
aerob
bacteri
cultur
e
coli
genotyp
rotaviru
coronaviru
test
perform
calv
onset
diarrhea
cornel
anim
health
diagnost
center
ithaca
ny
anim
sever
diarrhea
symptom
support
aggress
includ
administr
oral
electrolyt
intraven
fluid
flunixin
meglumin
banamin
merck
need
suspend
pk
studi
carboxymethylcellulos
water
tween
final
volum
ml
per
dose
administ
oral
squirt
dose
calv
mouth
interrupt
bottl
feed
daili
fecal
sampl
obtain
collect
bin
locat
pen
fecal
sampl
use
parasit
quantif
dri
stabl
weight
c
parvum
abund
per
gram
fecal
dri
matter
measur
use
qpcr
primer
forward
vitro
safeti
profil
studi
conduct
ricerca
bioscienc
taipei
taiwan
wuxi
apptec
suzhou
china
ricerca
perform
lead
profil
advers
reaction
enzym
panel
offtarget
enzym
receptor
includ
herg
k
ion
channel
associ
cardiac
tachyarrhythmia
use
radioligand
bind
competit
format
test
compound
h
enzym
receptor
panel
competit
inhibit
test
compound
common
assay
format
ame
bacteri
revers
mutat
assay
detect
point
mutat
escherichia
coli
salmonella
typhimurium
indic
mutagen
activ
bacteri
strain
obtain
molecular
toxicolog
boon
nc
wuxi
test
five
strain
without
aroclor
induc
rat
liver
triplic
test
mutagen
activ
dose
rang
per
plate
vitro
micronucleu
genotox
assay
perform
assess
clastogenicaneugen
potenti
wuxi
test
human
lymphocyt
without
h
use
rang
concentr
per
ml
duplic
observ
microscopi
induct
micronucl
human
lymphocyt
repeat
oral
dose
toxic
separ
toxicokinet
tk
studi
perform
male
rat
wuxi
apptec
compani
suzhou
china
studi
review
approv
wuxi
apptec
institut
anim
care
use
committe
staff
veterinarian
monitor
anim
welfar
issu
anim
individu
hous
solid
bottom
plastic
cage
bed
complianc
us
anim
welfar
act
rat
studi
perform
use
spraguedawley
male
rat
rattu
novegicu
crl
cd
sd
vafplu
weigh
g
start
compound
dose
repeat
oral
dose
toxic
studi
perform
use
vehicl
wv
methyl
cellulos
wv
sodium
dodecyl
sulfat
purifi
water
control
treatment
group
rat
dose
mg
per
kg
daili
oral
gavag
consecut
day
cage
side
clinic
observ
condit
behavior
ie
gait
stool
activ
level
atonia
coat
soil
groom
skin
turgor
postur
priapism
piloerect
perform
twice
daili
dose
phase
weight
food
consumpt
measur
daili
termin
studi
anim
evalu
erythrocyt
count
absolut
reticulocyt
count
alkalin
phosphatas
triglycerid
fast
anim
overnight
obtain
blood
abdomin
aorta
necropsi
termin
procedur
deep
anesthesia
pentobarbit
complet
necropsi
histopatholog
studi
hematoxylin
eosin
stain
larg
intestin
small
intestin
stomach
gross
lesion
perform
anim
day
dose
tk
studi
perform
parallel
determin
exposur
use
vehicl
control
anim
experiment
anim
dose
mg
per
kg
oral
gavag
daili
consecut
day
serum
collect
vehiclecontrol
anim
h
h
dose
day
recipi
group
divid
two
serum
collect
accord
follow
schedul
first
anim
predos
h
h
h
h
post
dose
day
h
time
point
day
second
anim
h
h
h
h
post
dose
day
h
time
point
day
follow
complet
blood
collect
tk
anim
euthan
inhal
exsanguin
without
necropsi
quantifi
use
qualifi
liquid
chromatograph
tripl
quadrupl
mass
spectrometr
lcmsm
method
lower
limit
quantif
ng
per
ml
graphpad
prism
softwar
version
use
prepar
graph
calcul
compound
valu
perform
statist
analys
limit
detect
lod
qpcr
fecal
oocyst
detect
assay
oocyst
per
gram
dri
fece
sampl
signal
detect
set
lod
purpos
graph
statist
analysi
indic
statist
signific
assess
use
oneway
anova
test
dunnett
method
multipl
comparison
graph
export
ep
file
final
figur
prepar
use
adob
illustr
inform
research
design
avail
natur
research
report
summari
link
articl
